Home » TB Trials Must Reflect Properties of Experimental Drugs
TB Trials Must Reflect Properties of Experimental Drugs
July 15, 2008
Patient recruitment and other aspects of tuberculosis (TB) clinical trials must be tailored to the properties of the agent being tested, according to a draft guideline from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor